Evotec AG, Company presentation, Jefferies 2015 Global Healthcare Conference, 04 June 2015, New York

Innovation Efficiency –

Evotec Company Overview

PAGE

Forward-looking statements

1

Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

PAGE

Agenda

2

Evotec at a glance

Innovation efficiency

Financials & outlook

PAGE

Leadership in drug discovery

3

Our mission

Based on the highest quality drug discovery science, and through innovative collaborations, we are building a partnered product pipeline.

PAGE

Clear long-term strategy

4

Strategy overview – Action Plan 2016

• Business segmentation

• Investments in discovery service platform

• Performance-based integrated discovery and clinical alliances

• Cure X/Target X strategy

• Restructuring

• Capital efficiency for sustainability

• First EVT Innovate investments

2009 • Partnered product pipeline to gain

milestones and royalties

• Highest quality discovery and pre-clinical service – EVT Execute

• “Academic bridge” and Cure X/Target X strategy – EVT Innovate

2012 2015

2020

PAGE 5

Improving R&D capital efficiency Pre-clinical development candidate “PDC” – Evotec’s “Sweet spot”

Source: Paul et al. Nature Reviews 9: 2013

Duration

Phase II Phase III Approval

Academia Target ID/-Vali-dation

Hit-Identi- fication

Lead Optimi- sation

Phase I Pre-clinical

> 14 years

Market

Cost Approx. $ 1–3 bn

Partner Evotec

Clinical Phase

Pre-clinical Phase

Approx. 3–6 years Approx. 6–10 years

PDC – Pre-clinical development

candidate

Evotec’s core competencies

Approx. $ 5–15 m

PAGE

The megatrend – Improvement of R&D productivity

6

Market dynamics in drug discovery

Source: Visiongain; Drug Discovery Outsourcing: World Market 2015

Growth driver Drug discovery outsourcing is a macro trend Market overview – Revenues, in $ bn

1 Increasing comfort with outsourcing

2 Higher R&D capital efficiency for innovation

3 Ability to adjust investments proportional to portfolio 2012

11.1

2015(e)

16.6

2014

14.5

2013

12.8

2017(e) 2018(e)

24.5 21.8

2016(e)

19.2

5–10% p.a.

PAGE

A global company with a complete offering

7

Evotec’s footprint

San Francisco, Branford and Princeton, USA ~65 employees • Compound ID, selection and

acquisition • Compound QC, storage and

distribution • Cell & Protein production

Abingdon and Manchester, UK ~280 employees • Medicinal chemistry • ADMET • Structural biology • In vitro & in vivo Anti-infective

platform/screening

Hamburg (HQ), Göttingen and Munich, Germany ~375 employees • Hit identification • In vitro & in vivo biology • Chemical proteomics &

Biomarker discovery and validation

• Cell & protein production

Toulouse, France ~210 employees • Compound management • Hit identification • In vitro & in vivo oncology • Medicinal chemistry • ADME & PK • Early drug formulation & Solid

form screening • Cell, protein & antibody

production

PAGE

Significant Sanofi alliance initiated in 2015

8

Summary of Sanofi alliance1) & Next steps

• Guaranteed commitment of approx. € 250 m over the next five years, including upfront cash receipts of more than € 40 m

• Master service agreement for drug discovery services with Sanofi improves revenue growth and profitability

• Increased capacity for EVT Innovate and EVT Execute with minimal Evotec funded Capex investment and dilution to shareholders

• Addition of first-class team with significant oncology expertise

• Addition of more than 15 oncology projects

• Sanofi screening library available for third-party collaborations

• “Bridge” from academia to Pharma in France & EU

Financials

Pipeline & Innovation

Next steps • Expansion of Pharma and biotech

service network

• Offering of combined libraries of 1.7 million compounds for third-party screening

• Build a sustainable oncology pipeline by progressing development stage projects towards IND

• Accelerate discovery stage projects and progress towards PDC nomination

• Expand academic network in France for future Cure X/Target X initiatives

1) Closing on 31 March 2015 (effective 01 April 2015)

PAGE

Agenda

9

Evotec at a glance

Innovation efficiency

Financials & outlook

PAGE

ONE company – TWO segments

10

EVT Execute & EVT Innovate

PAGE

EVT Execute – Comprehensive drug discovery platforms

Broad stand-alone innovation services

11

High-quality service business

The “Western” strategic outsourcing partner of choice

PAGE

Focus on causes not symptoms

12

EVT Innovate – Systematic, unbiased, comprehensive drug discovery

OTHER FIELDS OF KEY EXPERTISE Pain Anti-infectives Anti-inflammatory

NEUROSCIENCE Patient-derived iPS

cells as disease models with initial focus

in neurodegeneration

DIABETES & DIABETIC COMPLICATIONS Accessing unlimited supply of human beta cells; Pursuing podocyte-related mechanisms

ONCOLOGY Novel targeted therapies

Cancer immunity & cancer cell metabolism Resistance to SoC therapies

PAGE

Fast growing portfolio of > 70 product opportunities

13 1) RO4602522; Name of compound recently changed to Sembragiline by Roche 2) Not disclosed

Partnership portfolio

Molecule Indication Partner Discovery Pre-clinical Phase I Phase II Phase III

Clin

ical

EVT3021) AD

EVT201 Insomnia Somatoprim Acromegaly EVT100 CNS diseases

EVT401 Inflammation ND2) Oncology ND2) Oncology

Pre-

clin

ical

ND2) Pain ND2) Oncology Various Endometriosis EVT770 Diabetes – type 2/1 ND2) Pain ND2) Inflammation Various Oncology

Dis

cove

ry

Various Inflammation Various Diabetes – type 2/1 Various Diabetes – type 2/1 Various Kidney disease Various Oncology Various Alzheimer’s disease Various Oncology Various CNS/MS NEU2 Various Diabetes >5 further programmes Various Neurology >5 further programmes Various Oncology >10 further programmes Various Pain & Inflammation >5 further programmes

PAGE

Significant options in CNS

14

Neurology overview

1) RO4602522; Name of compound recently changed to Sembragiline by Roche 2) Not disclosed

Molecule(s) Indication (mechanism) Partner Status Next milestone Commercials

EVT3021) Alzheimer’s disease (MAO-B)

Phase IIb, recruitment completed

Completion of Phase II, Phase III start

$ 10 m upfront, up to $ 820 m milestones, significant royalties

EVT201 Insomnia Phase II Start clinical trials Milestones, royalties

EVT100 series CNS diseases (TRD) Phase II/Pre-clinical Confirmation of pre-clinical study/ Phase II start

$ 2 m upfront, up to $ 173 m milestones, significant royalties

Various CNS/Multiple sclerosis NEU2 Pre-clinical/Various ND2) ND2)

Various Huntington’s disease

Discovery ND2) Research payments; fund up 52 FTEs

Not disclosed Neurodegeneration

Discovery ND2)

Research payments

Not disclosed Fabry’s disease Discovery ND2) Research payments

TargetAD Alzheimer’s disease (Novel MoA)

Discovery ND2)

Up to $ 10 m research payments, approx. $ 125-145 m milestones, royalties

TargetASIC Multiple sclerosis Undisclosed Pharma

Discovery Lead status

Co-funded

Orexin-1 Stress-related addictive disorder programme

ND2) ND2) Research payments

CureMN Amyotrophic lateral sclerosis (ALS)

ND2)

Pharma partnership

PAGE

Phase IIb data for Sembragiline expected in H1 2015

15

Product development alliance with

1) EVT 302/RG1577/ RO4602522 Source: Alzheimer’s Disease International

Sembragiline1)

• A potent small molecule inhibitor of monoamine oxidase-B (MAO-B)

• Reduces the formation of toxic reactive oxygen species in the brain of Alzheimer’s disease patients where over expression of MAO-B is postulated to contribute to neuronal damage

Status

• One of the very few late-stage small molecule AD clinical trials in this specific AD patient population

• Patient recruitment for Phase IIb, multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety in patients with moderate severity Alzheimer disease completed (n=495, 52 week trial)

Expected key milestones

• Results of Phase IIb trial expected in Q2 2015

Alzheimer’s disease (AD)

• AD is the most common form of dementia

• 44 m people diagnosed with dementia in 2013 worldwide

• Approx. 7.7 m new cases of dementia are diagnosed each year

PAGE

Strategic focus on diabetes and diabetic complications

16

Diabetes and diabetic complications overview

Project(s) Indication (mechanism) Partner Status Next milestone Commercials

EVT770 Type 1 and 2 diabetes (beta cell regeneration)

Pre-clinical Phase I € 5 m upfront, high margin research payments, up to € 254 m milestones, significant royalties

ALM Type 1 and 2 diabetes (beta cell regeneration)

Discovery Phase I € 2 m upfront, high margin research payments, up to € 183 m milestones/product, significant royalties

Various Kidney disease ND1) ND1) Undisclosed upfront, high margin research payments, milestones/product, royalties

TargetEEM Type 1 and 2 diabetes (enteroendocrine)

Discovery Pharma partnership

CureNephron Chronic kidney disease Discovery Pharma partnership

CureBeta Type 1 and 2 diabetes (beta cell regeneration)

Discovery Pharma partnership

1) Not disclosed

PAGE

World-class pipeline-building in oncology

17

EVT Innovate & Sanofi

Molecule(s) Indication (mechanism) Partner Status Next milestone Commercials

Somatoprim (DG3173)

Acromegaly/NET Phase IIa

Pharma partnership Consulting fees, royalties

ND1) Oncology Phase I ND1) Research payments, milestones, royalties

ND1) /Biomarker platform

Oncology Phase I ND1) Success-based milestones

ND1) Oncology Pre-clinical

ND1) Research payments, milestones, royalties

TargetCanMet Various (Epigenetic targets)

H2L2) ND1) Research payments, milestones, royalties

TargetKDM Various (Epigenetic targets)

Pre-clinical

Pharma partnership ND1)

TargetImmuniT Various (Immunotherapy)

Pre-clinical

Pharma partnership ND1)

TargetDBR Glioblastoma H2L2) Pharma partnership ND1)

KRas Oncology Dis-covery

ND1) ND1)

• Four pre-clinical oncology assets

• Multiple early discovery projects

• Multiple Cure X/Target X initiatives as opportunities

1) Not disclosed 2) Hit to Lead

PAGE

Significant partnerships in pain, inflammation and anti-infectives

18

Pain, inflammation and anti-infectives

1) Proof of Concept

Molecule(s) Indication (mechanism) Partner Status Next milestone Commercials

EVT401 Inflammation (P2X7 inhibitor)

Phase I/II Phase II start Up to € 60 m milestones, royalties

Various Endometriosis Pre-clinical Pre-clinical candidate

€ 12 m upfront, up to approx. € 580 m milestones, royalties

Various Various/Pain

Pre-clinical Phase I start Undisclosed upfront, research payments, milestones, royalties

Not disclosed Various/Pain Pre-clinical Successful PoC1) Research payments, milestones, royalties

Not disclosed Inflammation Pre-clinical Phase I start Undisclosed upfront payment, milestones, royalties

Various Inflammation Discovery Pre-clinical

Research payments, up to € 183 m milestones/product, significant royalties

TargetPicV Viral host targets Discovery Pre-clinical candidate

TargetPGB Antibiotics Discovery Pre-clinical candidate

Protein-arginine deiminases (PADs)

Inflammation Discovery Pre-clinical candidate

Research payments, milestones up to approx. $ 13 m

PAGE

Translating first-in-class science to Pharma

19 1) Today at least partly progressed under commercial partnership

“The Bridge”

CureBeta (Harvard Stem Cell Institute)

TargetImmuniT (Apeiron) TargetDBR (Yale) TargetSP (Internal) TargetFX (Internal) TargetPGB (Harvard) TargetKDM (Dana-Farber, Belfer) CureMN (Harvard) TargetEEM (Harvard) TargetAD1) (NBB/J&J)

CureNephron1) (Harvard, BWH, USC, AstraZeneca) TargetASIC1) (BMBF/undisclosed Pharma partner) Somatoprim (Aspireo) TargetPicV (Haplogen) TargetCanMet1) (Debiopharm)

TargetBCD (Internal) TargetSX (undisclosed) TargetDR (Internal) TargetColCan (Internal) TargetKX (undisclosed) TargetCytokine (DRFZ) Fraunhofer Initiative

French Academic Bridge Ohio State University New York University Office of Therapeutic Alliances …

2011 2012 2013 2014 2015

PAGE

Agenda

20

Evotec at a glance

Innovation efficiency

Financials & outlook

PAGE

Strong revenue performance in EVT Execute, outstanding gross margin in EVT Innovate

21

Condensed income statement based on segments for Q1 2015

in € m • Revenue in EVT

Execute: Primarily attributable to strong growth in base business especially in anti-infectives

• Increased invest-ment in Cure X/ Target X initiatives

• Positive adjusted EBITDA of € 3.5 m in EVT Execute due to solid gross margin

EVT Execute

EVT Innovate

Inter- segment

elimination Evotec Group

Revenues 23.1 3.8 (5.4) 21.5

Gross margin 24.8% 46.2% – 30.7%

• R&D expenses (0.1) (4.6) 0.9 (3.8)

• SG&A expenses (3.8) (1.3) – (5.1)

• Amortisation of intangible assets (0.5) (0.1) – (0.6)

• Other op. income (expenses), net (0.5) 0.1 – (0.4)

Operating income (loss) 0.7 (4.0) – (3.3)

EBITDA1) 3.5 (3.8) – (0.3)

1) Adjusted for changes in contingent considerations

PAGE 22

Key metrics

Revenues (in € m)

R&D expenses (in € m)

EBITDA adjusted1) (in € m)

Liquidity2) (in € m)

Alliances

Employees3)

55.3

>100

2010 2015e

72

>150

2010 2015e

6.1

15-20

2010 2015e

Accelerated path to growth and sustainability

1) 1) Adjusted for changes in contingent considerations 2) 2) Cash and cash equivalents; 3) 3) Effective on 01 April 2015, Evotec acquired Sanofi’s scientific operations in Toulouse, France; 2015 number including the employees from this transaction

70.4

>100

2010 2015e

519

> 950

2010 2015e

6.5

2010 2015e

PAGE 23

Guidance 20151)

1) Varies from the guidance provided in the Annual Report 2014 following the financial impact of the Sanofi transaction 2) EBITDA excludes impairments on intangible and tangible assets and goodwill as well as the total non-operating result 3) Excluding any potential cash outflow for M&A or similar transactions

Increase in revenue guidance, all other elements of guidance confirmed

• More than 35% growth excluding milestones, upfronts and licences due to Sanofi alliance (previously: more than 20%)

• Positive adjusted EBITDA2) • Liquidity is expected to be well in excess of € 100 m3)

• Increased R&D investments of approx. € 15–20 m in strategic Cure X and Target X initiatives to accelerate long-term clinical pipeline building

• Continued capacity and capability building with up to € 10 m

Double- digit top- line growth

Profitable

Accelerated investments

1

2

3

PAGE

Strong team for innovation Management & shareholder structure

Number of shares: 131.7 m Listing: Frankfurt TecDAX, OTCBB 52 week high/low: € 4.32/€ 2.42

Management Board • Werner Lanthaler (CEO)

Long-time experience in Pharma & biotech

• Mario Polywka (COO) 18 years Evotec experience

• Cord Dohrmann (CSO) Outstanding background in metabolics

• Colin Bond (CFO) Big industry multi-national background

Key scientific advisor • Doug Melton

Harvard University/HHMI

Supervisory Board • Wolfgang Plischke

Ex-Bayer • Walter Wenninger

Ex-Bayer • Claus Braestrup

Ex-Lundbeck • Paul Herrling

Ex-Novartis • Bernd Hirsch

Symrise AG • Iris Löw-Friedrich

UCB

24

68% Free float

~13.0%

6% TVM Capital 12% BVF1)

1% Management

13% Roland Oetker/ROI

1) BVF Partners L.P. and its affiliates

PAGE

EVT Execute

• New long-term deals with large and mid-sized Pharma and biotech

• New integrated technology/disease alliances

• Milestones from existing alliances

EVT Innovate

• Strong progress of clinical pipeline within partnerships

• Phase IIb data with Roche in AD alliance

• Expansion of network of top-class academic alliances

• Partnering of Cure X/Target X initiatives

25

Expected key milestones in 2015

Starting a strong 2015

PAGE 26

Reporting dates 2015

12 May

09 June

12 August

10 November

3M/Q1 Interim Report

AGM in Hamburg

6M/Q2 Interim Report

9M/Q3 Interim Report

Your contact:

Dr Werner Lanthaler Chief Executive Officer

+49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax werner.lanthaler@evotec.com